These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 18836085

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
    Uwagawa T, Misawa T, Tsutsui N, Ito R, Gocho T, Hirohara S, Sadaoka S, Yanaga K.
    Am J Clin Oncol; 2013 Feb; 36(1):44-8. PubMed ID: 22157216
    [Abstract] [Full Text] [Related]

  • 3. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
    Furukawa K, Uwagawa T, Iwase R, Haruki K, Fujiwara Y, Gocho T, Shiba H, Misawa T, Yanaga K.
    Anticancer Res; 2012 Nov; 32(11):5121-6. PubMed ID: 23155291
    [Abstract] [Full Text] [Related]

  • 4. Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case.
    Fujiwara Y, Shiba H, Uwagawa T, Futagawa Y, Misawa T, Yanaga K.
    Int Surg; 2015 Feb; 100(2):287-91. PubMed ID: 25692432
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.
    J Clin Oncol; 2006 Jan 20; 24(3):379-85. PubMed ID: 16344320
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
    Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR.
    J Clin Oncol; 2002 Mar 01; 20(5):1182-91. PubMed ID: 11870159
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
    Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K.
    Anticancer Res; 2009 Aug 01; 29(8):3173-8. PubMed ID: 19661331
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X, Li YH, Lin XB, Wang FH, Feng F, Xu RH, Jiang WQ, He YJ.
    Ai Zheng; 2009 Mar 01; 28(3):286-91. PubMed ID: 19619444
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.